Plain-English translation of ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether Ocrelizumab—a medication that helps control multiple sclerosis by reducing inflammation—can be given less frequently without affecting how well it works. If your MS has been stable for at least 18 months on the standard twice-yearly infusion schedule, this study will randomly assign you to receive the medication either once per year or twice per year to see if the less frequent schedule works just as well.
The standard schedule of infusions every 6 months works very well, but it comes with potential risks that increase with more frequent doses, including a higher chance of infections. Researchers believe that once your disease is controlled, this medication may work just as well if given less often, which could reduce those risks and make treatment easier to manage long-term.
You likely qualify if…
You likely don't qualify if…
After you have already been on the standard twice-yearly infusion schedule for at least 2 years with good disease control, you will be randomly assigned to receive your medication either once per year or twice per year for 2 more years. You will continue to have regular MRI scans to monitor your disease, and the study team will track whether your MS stays under control with whichever schedule you are assigned to.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
France